» Articles » PMID: 25550154

A Novel Collagen-nanohydroxyapatite MicroRNA-activated Scaffold for Tissue Engineering Applications Capable of Efficient Delivery of Both MiR-mimics and AntagomiRs to Human Mesenchymal Stem Cells

Overview
Specialty Pharmacology
Date 2015 Jan 1
PMID 25550154
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Manipulation of gene expression through the use of microRNAs (miRNAs) offers tremendous potential for the field of tissue engineering. However, the lack of sufficient site-specific and bioactive delivery systems has severely hampered the clinical translation of miRNA-based therapies. In this study, we developed a novel non-viral bioactive delivery platform for miRNA mimics and antagomiRs to allow for a vast range of therapeutic applications. By combining nanohydroxyapatite (nHA) particles with reporter miRNAs (nanomiRs) and collagen-nanohydroxyapatite scaffolds, this work introduces the first non-viral, non-lipid platform to date, capable of efficient delivery of mature miRNA molecules to human mesenchymal stem cells (hMSCs), a particularly difficult cell type to transfect effectively, with minimal treatment-associated cytotoxicity. Firstly, miRNAs were successfully delivered to hMSCs in monolayer, with internalisation efficiencies of 17.4 and 39.6% for nanomiR-mimics and nanoantagomiRs respectively, and both nanomiR-mimics and nanoantagomiRs yielded sustained interfering activity of greater than 90% in monolayer over 7 days. When applied to 3D scaffolds, significant RNA interference of 20% for nanomiR-mimics and 88.4% for nanoantagomiRs was achieved with no cytotoxicity issues over a 7 day period. In summary, in-house synthesised non-viral nHA particles efficiently delivered reporter miRNAs both in monolayer and on scaffolds demonstrating the immense potential of this innovative miRNA-activated scaffold system for tissue engineering applications.

Citing Articles

Advances in non-coding RNA in tendon injuries.

Wang B, Chen Q, Zou X, Zheng P, Zhu J Front Genet. 2024; 15:1396195.

PMID: 38836038 PMC: 11148651. DOI: 10.3389/fgene.2024.1396195.


Optimizing the Delivery of mRNA to Mesenchymal Stem Cells for Tissue Engineering Applications.

McCormick K, Moreno Herrero J, Haas H, Fattah S, Heise A, OBrien F Mol Pharm. 2024; 21(4):1662-1676.

PMID: 38504417 PMC: 10988554. DOI: 10.1021/acs.molpharmaceut.3c00898.


Non-viral gene delivery to human mesenchymal stem cells: a practical guide towards cell engineering.

Carballo-Pedrares N, Ponti F, Lopez-Seijas J, Miranda-Balbuena D, Bono N, Candiani G J Biol Eng. 2023; 17(1):49.

PMID: 37491322 PMC: 10369726. DOI: 10.1186/s13036-023-00363-7.


miRNA-encapsulated abiotic materials and biovectors for cutaneous and oral wound healing: Biogenesis, mechanisms, and delivery nanocarriers.

Dey A, Yousefiasl S, Kumar A, Dabbagh Moghaddam F, Rahimmanesh I, Samandari M Bioeng Transl Med. 2023; 8(1):e10343.

PMID: 36684081 PMC: 9842058. DOI: 10.1002/btm2.10343.


Development of a Gene-Activated Scaffold Incorporating Multifunctional Cell-Penetrating Peptides for pSDF-1α Delivery for Enhanced Angiogenesis in Tissue Engineering Applications.

Power R, Cavanagh B, Dixon J, Curtin C, OBrien F Int J Mol Sci. 2022; 23(3).

PMID: 35163379 PMC: 8835777. DOI: 10.3390/ijms23031460.